- Home
- NPFD vs DCTH Comparison
NPFD vs DCTH Comparison
Compare NPFD & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPFD
- DCTH
- Stock Information
- Founded
- NPFD 2021
- DCTH 1988
- Country
- NPFD United States
- DCTH United States
- Employees
- NPFD N/A
- DCTH N/A
- Industry
- NPFD Trusts Except Educational Religious and Charitable
- DCTH Medical/Dental Instruments
- Sector
- NPFD Finance
- DCTH Health Care
- Exchange
- NPFD Nasdaq
- DCTH Nasdaq
- Market Cap
- NPFD 462.7M
- DCTH 394.9M
- IPO Year
- NPFD N/A
- DCTH N/A
- Fundamental
- Price
- NPFD $19.53
- DCTH $11.12
- Analyst Decision
- NPFD
- DCTH Strong Buy
- Analyst Count
- NPFD 0
- DCTH 4
- Target Price
- NPFD N/A
- DCTH $24.50
- AVG Volume (30 Days)
- NPFD 64.7K
- DCTH 834.5K
- Earning Date
- NPFD 01-01-0001
- DCTH 08-06-2025
- Dividend Yield
- NPFD 6.28%
- DCTH N/A
- EPS Growth
- NPFD N/A
- DCTH N/A
- EPS
- NPFD N/A
- DCTH 0.06
- Revenue
- NPFD N/A
- DCTH $70,240,000.00
- Revenue This Year
- NPFD N/A
- DCTH $160.46
- Revenue Next Year
- NPFD N/A
- DCTH $42.87
- P/E Ratio
- NPFD N/A
- DCTH $198.75
- Revenue Growth
- NPFD N/A
- DCTH 491.35
- 52 Week Low
- NPFD $14.50
- DCTH $7.83
- 52 Week High
- NPFD $18.07
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- NPFD 59.37
- DCTH 50.82
- Support Level
- NPFD $19.18
- DCTH $10.06
- Resistance Level
- NPFD $19.57
- DCTH $10.81
- Average True Range (ATR)
- NPFD 0.16
- DCTH 0.75
- MACD
- NPFD -0.00
- DCTH 0.12
- Stochastic Oscillator
- NPFD 76.34
- DCTH 35.01
About NPFD Nuveen Variable Rate Preferred & Income Fund
Nuveen Variable Rate Preferred&Income is a newly organized, diversified, closed-end management investment company. The Fund's investment objective is to seek to provide a high level of current income and total return.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.